Unrivaled responses have been reported amongst advanced staged cancer patients, such as lung cancer, melanoma, bladder cancer, and Hodgkin’s disease, treated with anti-CTLA-4, PD-1/L1 therapies, although a minimal percentage of patients benefitted after such treatments. This evidence concerns the gene PDCD1 and urinary bladder carcinoma.